The study concluded that CXCL8 promotes tumor cell migration, invasion, and immune evasion through the CXCR1/2 axis, and blocking this signaling pathway can significantly improve the efficacy of immune checkpoint inhibitors, especially when used in combination with anti-PD-1, showing a pronounced anti-tumor effect [98]. This evidence concerns the gene CXCR1 and neoplasm.